Germ Cell Tumors

We provide an overview of the current checkpoint inhibitor landscape for pediatric brain tumors, highlight barriers and summarize possible approaches that can be efficaciously explored in future clinical trials.

Management of patients with GCT requires a multidisciplinary approach and patients with advanced disease being considered for surgery or those with refractory disease should be referred to a high-volume treatment center. Outcomes in refractory GCT remain poor, but several novel treatment options and approaches are being explored in clinical trials to improve cure rates in this patient population.

For clinicians managing Klinefelter patients, these findings emphasise the importance of vigilance for EGCTs, particularly in the mediastinum, even though routine testicular cancer surveillance beyond standard care may not be necessary in the absence of other risk factors. Our data do not support a need for intensive TGCT screening in KS at present, given the lack of a statistically significant increase in testicular cancer incidence. Conversely, the significantly elevated incidence of mediastinal GCT in KS raises the question of screening such as periodic chest imaging in adolescent KS patients. While universal screening is debatable due to the rarity of these tumours, a thorough physical exam (looking for mediastinal mass effects) and a low threshold for chest imaging if symptoms arise (e.g., chest pain, dyspnoea) are advisable in KS. In future, larger multi-centre cohort studies and cancer registry linkages (ideally capturing genotype-confirmed KS cases) will be needed to definitively quantify TGCT risk in KS and to explore the molecular underpinnings of the KS-GCT connection.

P3, N=223, Terminated, Hoffmann-La Roche | Completed --> Terminated; Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).

Clinically significant mutations (KIT: Asp816Val, Ala829Pro; and KRAS: Gln61Leu) suggest potential therapeutic targets for GCT, while MTOR, PIK3CA, and AKT2 emerge as candidates for targeted therapy. These findings provide insights into the genomic alterations of pediatric GCTs and emphasize the potential for targeted therapies.

P2, N=52, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

Recent advances in single-cell transcriptomics and clinical studies highlight the necessity for high-resolution characterization of T cell subpopulations and their intercellular interactions within the TGCT TME. Elucidating these mechanisms is critical for the rational development of novel immunotherapeutic strategies aimed at overcoming resistance, minimizing long-term treatment-related sequelae, and enhancing clinical outcomes for TGCT patients.

P=N/A, N=30, Recruiting, Queen Mary University of London | Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Oct 2025 --> Oct 2028

Meanwhile, it also activated the release of LDH, increased the activity of SOD and enhanced the level of MDA in NTERA-2 cells. These findings indicated that 8,3'-diprenylapigenin is a novel reversible LSD1 inhibitor and deserves further exploration to treat testicular germ cell tumors.

Next gene sequencing detected TP53 c.919+3del splice site variant and KRAS N116H. It is important to consider HMs when extramediastinal lesions or thrombocytopenia appear in patients with MGCT.

Brain biopsy revealed intracranial germinoma. The case herein presented highlights a rare presentation of an uncommon neuro-oncological condition that often demonstrates excellent treatment response but is often diagnosed late due to its non-specific presenting symptoms.